Comparison of agents that affect aldosterone action.

Area of Science:

• Pharmacology
• Endocrinology
• Nephrology

Background:

• Spironolactone, the first aldosterone blocker, had significant side effects limiting its use.
• Aldosterone's diverse receptor actions expanded indications for its blockers.
• Eplerenone offered better safety but lower potency than spironolactone.

Purpose of the Study:

• To review the evolution of aldosterone blockers.
• To highlight the development of newer generations of mineralocorticoid receptor antagonists and aldosterone synthase inhibitors.
• To identify the goals of new drug development in balancing efficacy and safety.

Main Methods:

• Literature review of aldosterone blockers.
• Analysis of historical and current clinical use of spironolactone and eplerenone.
• Overview of ongoing research into third and fourth-generation compounds.

Main Results:

• Spironolactone's side effects led to its withdrawal in some patients.
• Eplerenone improved safety but had reduced potency at equivalent doses.
• New nonsteroidal mineralocorticoid receptor antagonists and aldosterone synthase inhibitors are under development.

Conclusions:

• New aldosterone blockers aim to match spironolactone's efficacy while avoiding its side effects.
• Reduced hyperkalemia prevalence, especially in chronic kidney disease, is a key goal for new agents.
• Ongoing studies will determine the success of next-generation aldosterone blockers in clinical practice.